Drugs which aim to block the TGF-β signalling are under investigation in connection with several disorders such as hypertrophic cardiomyopathy [44], hypertension [45] or the Marfan syndrome [46] and are suggested to be valuable for treating food allergies [42]. Here, TGFB1 is linked to hypertrophic cardiomyopathy.